We have developed a unique corporate structure to develop our broad pipeline of oncology drug candidates. This corporate structure involves the formation of joint venture partnerships for select products in various territories to optimize our development efforts and corporate funding.
Our joint ventures have independent management and substantially independent funding sources, which allows each of our companies to focus on the development of their respective product candidates.
Our joint ventures include:
- Panacela Labs, Inc., formed in 2011 to develop new preclinical product candidates, primarily focused in oncology.
- Incuron, LLC - In 2015, CBLI divested its interest in Incuron, LLC, which was formed in 2010 to develop CBL0137 and its predecessor. CBLI retains a royalty on the future commercialization, licensing or sale of the CBL0137 technology and future change of control transaction of Incuron.